TY - JOUR
T1 - Dose-dependent effect of aerobic exercise on inflammatory biomarkers in a randomized controlled trial of women at high risk of breast cancer
AU - Haley, Jeremy S.
AU - Hibler, Elizabeth A.
AU - Zhou, Shouhao
AU - Schmitz, Kathryn H.
AU - Sturgeon, Kathleen M.
N1 - Funding Information:
Kathryn H. Schmitz has received a grant from the National Cancer Institute (grant R01CA13133) for work performed as part of the current study. Kathleen M. Sturgeon has received grants from the National Center for Advancing Translational Sciences (UL1 TR002014 and KL2 TR002015) and nonfinancial support from the National Cancer Institute (grant R25CA203650) for work performed as part of the current study. The other authors made no disclosures. Supported by the National Center for Advancing Translational Sciences (grants UL1 TR002014 and KL2 TR002015) and the National Cancer Institute at the National Institutes of Health (grants R01CA131333 and R25CA203650).
Publisher Copyright:
© 2019 American Cancer Society
PY - 2020/1/15
Y1 - 2020/1/15
N2 - Background: Increased levels of inflammation are associated with many diseases, including cancer. Physical activity can lower breast cancer risk as well as levels of inflammation. The Women In Steady Exercise Research (WISER) Sister trial was a randomized controlled trial that investigated the effects of a dosed, moderate to vigorous, aerobic exercise intervention on levels of inflammation in premenopausal women who were at high risk of developing breast cancer. Methods: Participants were randomized to control (<75 minutes per week; 41 patients), low-dose exercise (150 minutes per week; 38 patients), or high-dose exercise (300 minutes per week; 37 patients) groups. The 5-menstrual cycles–long, home-based treadmill exercise intervention gradually increased in minutes per week and intensity up to a maximum of 80% of the age-predicted maximum heart rate. Blood was collected at baseline and at follow-up and assayed for chemokine (C-C motif) ligand 2 (CCL2), interleukin 10 (IL-10), interleukin 12 (IL-12), and tumor necrosis factor α (TNF-α). Results: A linear dose-response relationship was observed for the proinflammatory biomarkers CCL2 (%Δ of −5.44% in the control group, −0.03% in the low-dose exercise group, and 1.54% in the high-dose exercise group), IL-12 (%Δ of −21.5% in the control group, 38.2% in the low-dose exercise group, and 25.8% in the high-dose exercise group,) and TNF-α (%Δ of −4.69% in the control group, 9.51% in the low-dose exercise group, and 15.7% in the high-dose exercise group) but not for the anti-inflammatory biomarker IL-10 (%Δ of 5.05% in the control group, 6.05% in the low-dose exercise group, and 10.6% in the high-dose exercise group). For IL-12 and TNF-α, the percentage change was significantly higher in the low-dose (IL-12: P <.001; and TNF-α: P =.01) and high-dose (IL-12: P <.001; and TNF-α: P <.001) exercise groups compared with the control group. Conclusions: Moderate to vigorous aerobic exercise appeared to increase levels of proinflammatory biomarkers in a dose-dependent manner in a population of healthy women at high risk of developing breast cancer. The results of the current study suggest that for healthy premenopausal women, the mechanism of reduced breast cancer risk observed in physically active individuals may not be a result of reduced levels of inflammation.
AB - Background: Increased levels of inflammation are associated with many diseases, including cancer. Physical activity can lower breast cancer risk as well as levels of inflammation. The Women In Steady Exercise Research (WISER) Sister trial was a randomized controlled trial that investigated the effects of a dosed, moderate to vigorous, aerobic exercise intervention on levels of inflammation in premenopausal women who were at high risk of developing breast cancer. Methods: Participants were randomized to control (<75 minutes per week; 41 patients), low-dose exercise (150 minutes per week; 38 patients), or high-dose exercise (300 minutes per week; 37 patients) groups. The 5-menstrual cycles–long, home-based treadmill exercise intervention gradually increased in minutes per week and intensity up to a maximum of 80% of the age-predicted maximum heart rate. Blood was collected at baseline and at follow-up and assayed for chemokine (C-C motif) ligand 2 (CCL2), interleukin 10 (IL-10), interleukin 12 (IL-12), and tumor necrosis factor α (TNF-α). Results: A linear dose-response relationship was observed for the proinflammatory biomarkers CCL2 (%Δ of −5.44% in the control group, −0.03% in the low-dose exercise group, and 1.54% in the high-dose exercise group), IL-12 (%Δ of −21.5% in the control group, 38.2% in the low-dose exercise group, and 25.8% in the high-dose exercise group,) and TNF-α (%Δ of −4.69% in the control group, 9.51% in the low-dose exercise group, and 15.7% in the high-dose exercise group) but not for the anti-inflammatory biomarker IL-10 (%Δ of 5.05% in the control group, 6.05% in the low-dose exercise group, and 10.6% in the high-dose exercise group). For IL-12 and TNF-α, the percentage change was significantly higher in the low-dose (IL-12: P <.001; and TNF-α: P =.01) and high-dose (IL-12: P <.001; and TNF-α: P <.001) exercise groups compared with the control group. Conclusions: Moderate to vigorous aerobic exercise appeared to increase levels of proinflammatory biomarkers in a dose-dependent manner in a population of healthy women at high risk of developing breast cancer. The results of the current study suggest that for healthy premenopausal women, the mechanism of reduced breast cancer risk observed in physically active individuals may not be a result of reduced levels of inflammation.
KW - BRCA
KW - aerobic exercise
KW - biomarkers
KW - breast cancer
KW - inflammation
KW - physical activity
UR - http://www.scopus.com/inward/record.url?scp=85073938431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073938431&partnerID=8YFLogxK
U2 - 10.1002/cncr.32530
DO - 10.1002/cncr.32530
M3 - Article
C2 - 31568587
AN - SCOPUS:85073938431
SN - 0008-543X
VL - 126
SP - 329
EP - 336
JO - cancer
JF - cancer
IS - 2
ER -